Document Detail

Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
MedLine Citation:
PMID:  23266049     Owner:  NLM     Status:  Publisher    
BACKGROUND AND OBJECTIVE: The survival outcomes of patients with metastatic nasopharyngeal carcinoma (NPC) differ significantly between individuals. This study aimed to evaluate whether serum lactic dehydrogenase (S-LDH) level had a clinical value in predicting clinical response and survival outcome for patients with metastatic NPC. METHODS: S-LDH level was measured at baseline and then before every cycle of treatment in 689 NPC patients with distant metastases. Correlations of pre-treatment and post-treatment S-LDH levels to response of treatment and survival were analysed retrospectively. RESULTS: Patients with elevated values of pre-treatment S-LDH (>245IU/L) had significantly worse survival than those with normal values of pre-treatment S-LDH (⩽245IU/L) (P<0.001). Patients with elevated values of post-treatment S-LDH had worse survival compared with those with normal values of post-treatment S-LDH (P<0.001). Patients with normal values of pre-treatment and post-treatment S-LDH showed the highest response rate and the most favourable prognosis. CONCLUSION: S-LDH appears to be a significant independent prognostic index in patients with disseminated NPC that should be considered in the comparison of the results achieved with different therapies and in planning new randomised clinical therapeutic trials.
Y Jin; X Ye; L Shao; B C Lin; C X He; B B Zhang; Y P Zhang
Related Documents :
2050159 - Cervical stump carcinoma therapy.
23817299 - Neuroendocrine neoplasms of the stomach.
23233719 - Randomized phase iii placebo-controlled trial of letrozole plus oral temsirolimus as fi...
19661369 - Efficiency of iloprost treatment for chemotherapy-associated osteonecrosis after childh...
24615109 - Association of cyclin d1 and survivin expression with sensitivity to radiotherapy in pa...
21966189 - Intravitreal bevacizumab for delayed radiation maculopathy and papillopathy after irrad...
7459899 - High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-fu, and hydroxyurea...
17875059 - Surgical results and prognosis of patients with primary bronchogenic carcinoma aged les...
25289169 - Long-term outcome of gamma knife radiosurgery for metastatic brain tumors originating f...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-21
Journal Detail:
Title:  European journal of cancer (Oxford, England : 1990)     Volume:  -     ISSN:  1879-0852     ISO Abbreviation:  Eur. J. Cancer     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9005373     Medline TA:  Eur J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Department of Medical Oncology, Zhejiang Cancer Hospital, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Childhood acute lymphoblastic leukaemia and birthweight: Insights from a pooled analysis of case-con...
Next Document:  Spectroscopic studies of the effects of anticancer drug mitoxantrone interaction with calf-thymus DN...